Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $0.49M |
| Net Income (Most Recent Fiscal Year) | $-41.44M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 381.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -8492.01% |
| Net Margin (Trailing 12 Months) | -8492.01% |
| Return on Equity (Trailing 12 Months) | -50.13% |
| Return on Assets (Trailing 12 Months) | -44.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.41 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.41 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.93 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 44.68M |
| Free Float | 41.86M |
| Market Capitalization | $186.30M |
| Average Volume (Last 20 Days) | 0.92M |
| Beta (Past 60 Months) | 1.94 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.29% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |